BRIEF published on 06/27/2024 at 18:20, 1 year 8 months ago Dermapharm Holding SE : l'Assemblée générale annuelle décide de distribuer un dividende de 0,88 EUR par action Dividende Assemblée Générale Annuelle Perspectives Financières Dermapharm
PRESS RELEASE published on 06/27/2024 at 18:15, 1 year 8 months ago Dermapharm Holding SE: Annual General Meeting resolves dividend distribution of EUR 0.88 per share Dermapharm Holding SE's Annual General Meeting approves EUR 0.88 per share dividend distribution for 2024. Board actions confirmed. Outlook and acquisitions strategies highlighted Annual General Meeting Acquisitions Outlook Dividend Distribution Dermapharm Holding SE
BRIEF published on 05/15/2024 at 07:35, 1 year 10 months ago Dermapharm Holding SE annonce une baisse de son chiffre d'affaires au premier trimestre 2024 dans un contexte de forte croissance des produits pharmaceutiques de marque Résultats Financiers Croissance Organique Résilience Du Marché Produits De Santé Produits Pharmaceutiques De Marque
BRIEF published on 05/15/2024 at 07:35, 1 year 10 months ago Dermapharm Holding SE Reports Decline in Q1 2024 Revenue Amidst Strong Branded Pharmaceuticals Growth Financial Results Organic Growth Market Resilience Healthcare Products Branded Pharmaceuticals
PRESS RELEASE published on 05/15/2024 at 07:30, 1 year 10 months ago Strong organic growth in core markets underscores resilience of Dermapharm Holding SE's corporate strategy Dermapharm Holding SE reports strong organic growth in core markets with resilient corporate strategy in Q1 2024 Organic Growth Q1 2024 Core Markets Dermapharm Holding SE Resilient Strategy
BRIEF published on 03/28/2024 at 07:35, 1 year 11 months ago Dermapharm Holding SE répond à toutes les attentes dans un contexte économique difficile Rapport Annuel 2023 Défis Économiques Dermapharm Holding SE Industrie Pharmaceutique Attentes De Croissance
BRIEF published on 03/28/2024 at 07:35, 1 year 11 months ago Dermapharm Holding SE Meets All Expectations in Challenging Economic Climate Pharmaceutical Industry Annual Report 2023 Economic Challenges Dermapharm Holding SE Growth Expectations
PRESS RELEASE published on 03/28/2024 at 07:30, 1 year 11 months ago Dermapharm Holding SE fulfils all expectations despite multiple macroeconomic challenges Dermapharm Holding SE fulfils all expectations in 2023 despite macroeconomic challenges, with revenue up by 10.8% to EUR 1,135.4 million and adjusted EBITDA margin at 27.3% Pharmaceutical Industry Revenue Growth EBITDA Margin Annual Report Dermapharm Holding SE
BRIEF published on 03/14/2024 at 07:35, 2 years ago Dermapharm Holding SE atteint l'extrémité supérieure de sa fourchette d'orientation malgré les défis Résultats Financiers Hausse Des Revenus Médicaments Dermapharm Holding SE Produits De Santé
BRIEF published on 03/14/2024 at 07:35, 2 years ago Dermapharm Holding SE Achieves Top End of Guidance Range Amid Challenges Financial Results Revenue Growth Pharmaceuticals Dermapharm Holding SE Healthcare Products
Published on 03/26/2026 at 23:00, 5 hours 42 minutes ago FutureGen Industries Announces Closing of Debt Settlement
Published on 03/26/2026 at 22:05, 6 hours 37 minutes ago BlackBerry to Announce Fourth Quarter and Fiscal Year 2026 Results on April 9, 2026
Published on 03/26/2026 at 22:00, 6 hours 42 minutes ago Clean Air Metals Receives Provincial Funding and Provides Update on the Thunder Bay North Project
Published on 03/26/2026 at 22:00, 6 hours 42 minutes ago Green Bridge Metals Reports Visible Copper Sulfide Mineralization in Initial 2026 Titac Drilling, Duluth Complex Minnesota
Published on 03/26/2026 at 21:00, 7 hours 42 minutes ago Worksport Reports Record FY 2025 Results, Issues $35M–$42M 2026 Revenue Guidance; Targets Initial Cash Flow Positivity
Published on 03/27/2026 at 04:00, 42 minutes ago Tech-Driven Restoration: Saving the World's Critically Endangered White-headed Langur
Published on 03/26/2026 at 20:48, 7 hours 54 minutes ago Dermapharm Holding SE repurchases 4,299,190 shares under its public share buyback offer
Published on 03/26/2026 at 19:20, 9 hours 22 minutes ago Critical Path Institute Launches 'One to Millions' to Reshape the Future of Individualized Medicine at Global Scale
Published on 03/26/2026 at 19:09, 9 hours 32 minutes ago 2CRSi SA: Résultats 1er Semestre 2025/26 : Chiffre d'Affaires 204,7 M€ (x9,8) EBITDA de 9,6 M€ (x4,6)
Published on 03/26/2026 at 18:17, 10 hours 25 minutes ago Eiffage se renforce au capital de Getlink et porte sa participation à 29,40 % du capital
Published on 03/26/2026 at 18:17, 10 hours 25 minutes ago Eiffage strengthens its position in Getlink capital
Published on 03/26/2026 at 18:00, 10 hours 42 minutes ago Arrêté des comptes au 31 décembre 2025 et perspectives 2026
Published on 03/26/2026 at 18:00, 10 hours 42 minutes ago LABORATOIRES EUROMEDIS - Fin du contrat de liquidité
